Aug 25, 2020 7:30 am EDT Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis
Jun 29, 2020 7:30 am EDT Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis
May 14, 2020 7:30 am EDT Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement
Apr 16, 2020 4:01 pm EDT Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Mar 30, 2020 7:30 am EDT Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease
Feb 14, 2020 7:00 am EST Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019